A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer

Jana Soukupova,Barbora Stastna,Madiha Kanwal,Jan Hojny,Petra Zemankova,Marianna Borecka,Leona Cerna,Marta Cerna,Monika Cerna,Vaclava Curtisova,Tatana Dolezalova,Petra Duskova,Lenka Foretova,Ondrej Havranek,Klara Horackova,Milena Hovhannisyan,Lucie Hruskova,Stepan Chvojka,Marketa Janatova,Maria Janikova,Sandra Jelinkova,Pavel Just,Marta Kalousova,Petra Kleiblova,Marcela Kosarova,Monika Koudova,Jan Kral,Michaela Krausova,Vera Krutilkova,Eva Machackova,Katerina Matejkova,Renata Michalovska,Petr Nehasil,Barbora Nemcova,Jan Novotny,Matous Palek,Pavel Pesek,Marketa Safarikova,Ondrej Scheinost,Drahomira Springer,Lenka Stolarova,Viktor Stranecky,Ivan Subrt,Spiros Tavandzis,Eva Tureckova,Kamila Vesela,Zdenka Vlckova,Michal Vocka,Tomas Zima,Libor Macurek,Zdenek Kleibl,the CZECANCA consortium

DOI: https://doi.org/10.1002/cam4.70103

IF: 4.711

2024-08-18

Cancer Medicine

Abstract:FANCG, together with established breast/ovarian predisposition genes BRCA1 and BRCA2 belongs to the Fanconi anemia gene family; however, little is known about cancer predisposition in carriers of FANCG germline alterations. Here we demonstrate that these individuals does not have increased breast and ovarian cancer risk, because the frequency of FANCG pathogenic variants among cancer patients are not different from that in controls, the tumors in FANCG carriers showed no loss‐of‐heterozygozity of wild type allele, and functional in vitro analysis found that any tested rare missense variant impaired FANCG capacity in DNA repair. Background Monoallelic germline pathogenic variants (GPVs) in five Fanconi anemia (FA) genes (BRCA1/FANCS, BRCA2/FANCD1, PALB2/FANCN, BRIP1/FANCJ, and RAD51C/FANCO) confer an increased risk of breast (BC) and/or ovarian (OC) cancer, but the role of GPVs in 17 other FA genes remains unclear. Methods Here, we investigated the association of germline variants in FANCG/XRCC9 with BC and OC risk. Results The frequency of truncating GPVs in FANCG did not differ between BC (20/10,204; 0.20%) and OC (8/2966; 0.27%) patients compared to controls (6/3250; 0.18%). In addition, only one out of five tumor samples showed loss‐of‐heterozygosity of the wild‐type FANCG allele. Finally, none of the nine functionally tested rare recurrent missense FANCG variants impaired DNA repair activities (FANCD2 monoubiquitination and FANCD2 foci formation) upon DNA damage, in contrast to all tested FANCG truncations. Conclusion Our study suggests that heterozygous germline FANCG variants are unlikely to contribute to the development of BC or OC.

oncology